Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
ProShares Ultra Nasdaq Biotechnology (BIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: BIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 27.3% | Avg. Invested days 53 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Volume (30-day avg) - | Beta 1.16 | 52 Weeks Range 33.65 - 68.43 | Updated Date 06/29/2025 |
52 Weeks Range 33.65 - 68.43 | Updated Date 06/29/2025 |
Upturn AI SWOT
ProShares Ultra Nasdaq Biotechnology
ETF Overview
Overview
The ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF that seeks to deliver twice (2x) the daily performance of the Nasdaq Biotechnology Index. It focuses on the biotechnology sector, primarily holding stocks of companies involved in biotechnology and pharmaceuticals. The fund employs a leveraged strategy, meaning it uses financial derivatives and debt to amplify investment returns and risks.
Reputation and Reliability
ProShares is a well-known issuer of leveraged and inverse ETFs, generally considered reputable, although their products are inherently riskier due to the leveraged nature.
Management Expertise
ProShares has extensive experience managing leveraged and inverse ETFs, requiring specialized expertise in financial derivatives and portfolio management.
Investment Objective
Goal
The ETF aims to provide investment results that correspond to twice (2x) the daily performance of the Nasdaq Biotechnology Index.
Investment Approach and Strategy
Strategy: The ETF seeks to achieve its objective by investing in financial instruments such as swap agreements, futures contracts, and options contracts with the intention of producing investment results that correlate to twice the daily performance of the Nasdaq Biotechnology Index.
Composition The ETF primarily holds derivatives such as swap agreements to achieve its leveraged exposure to the Nasdaq Biotechnology Index.
Market Position
Market Share: BIB's market share within the leveraged biotechnology ETF space is significant, though this is a niche market segment.
Total Net Assets (AUM): 148758512.45
Competitors
Key Competitors
- LABU
- BIS
Competitive Landscape
The leveraged biotechnology ETF industry is relatively concentrated. LABU is the largest competitor of BIB in the 3x leverage biotechnology space. BIB is has a smaller market share compared to LABU but a higher volume.
Financial Performance
Historical Performance: Past performance is not indicative of future results. Due to the leveraged nature of the ETF, its performance can be highly volatile and may not track the index's performance over longer periods.
Benchmark Comparison: Due to the daily leverage, the ETF's long-term performance will likely deviate significantly from twice the Nasdaq Biotechnology Index's performance.
Expense Ratio: 0.95
Liquidity
Average Trading Volume
The average daily trading volume of BIB is relatively high, indicating good liquidity.
Bid-Ask Spread
The bid-ask spread is generally tight, implying relatively low trading costs.
Market Dynamics
Market Environment Factors
The ETF's performance is highly sensitive to the biotechnology sector's performance, influenced by factors like FDA approvals, clinical trial results, and overall market sentiment towards healthcare.
Growth Trajectory
The growth trajectory is tied to the biotech industry's performance and investor appetite for leveraged products; strategy and holdings will likely remain consistent.
Moat and Competitive Advantages
Competitive Edge
BIB's competitive advantage lies primarily in its focus on providing leveraged exposure to the Nasdaq Biotechnology Index. This specialized focus caters to investors seeking to amplify their returns (and risks) on short-term movements in the biotech sector. Its leverage provides a distinct offering compared to non-leveraged ETFs. However, this leverage also introduces significant risks, making it unsuitable for some investors. Its management team and ProShares' experience are also advantages.
Risk Analysis
Volatility
The ETF exhibits very high volatility due to its leveraged nature, making it susceptible to significant price swings.
Market Risk
The ETF is exposed to the market risk of the biotechnology sector, which is influenced by factors like regulatory changes, drug pricing pressures, and scientific breakthroughs.
Investor Profile
Ideal Investor Profile
The ideal investor is a sophisticated trader with a high-risk tolerance, a short-term investment horizon, and a strong understanding of leveraged ETFs and the biotechnology sector.
Market Risk
This ETF is best suited for active traders seeking short-term gains and not for long-term investors or passive index followers.
Summary
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF designed to provide twice the daily performance of the Nasdaq Biotechnology Index. It's a high-risk, high-reward product suitable for sophisticated traders with a short-term focus. Its performance is highly sensitive to the biotechnology sector's movements, magnified by its leveraged strategy. Investors should be aware of the significant risks associated with leveraged ETFs and the potential for substantial losses.
Similar ETFs
Sources and Disclaimers
Data Sources:
- ProShares Website
- ETF.com
- Yahoo Finance
- Bloomberg
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Investing in ETFs involves risk, including the potential loss of principal. Leveraged ETFs are particularly risky and are not suitable for all investors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProShares Ultra Nasdaq Biotechnology
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.